Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
aNPuGyQsJZNzqXt9
